LES Foundation | LESI | Print Page | Contact Us | Sign In | Join
LytPhage – Story of local resources leading to identification of the commercial path
Tell a Friend About This EventTell a Friend
 

LES Philadelphia Chapter Meeting

4/23/2015
When: Thursday, April 23, 2015
6:00 pm - 8:30 pm
Where: Quorum University City Science Center
3711 Market Street, Suite 800
Philadelphia, Pennsylvania  19104
United States

« Go to Upcoming Event List  

DATE & TIME
Thursday, April 23, 2015
6:00 PM - 8:30 PM
Networking Cocktail hour from 6-7:00 followed by a panel discussion

LOCATION
Quorum
University City Science Center
3711 Market Street, Suite 800
Philadelphia, PA 19104
https://www.sciencecenter.org

TITLE
LytPhage – Story of local resources leading to identification of the commercial path and company formation.

PANELISTS
David Hesson, PhD, CEO, LytPhage, LL
Ken Kilgore, MS, PhD, Director, Partnered Pharmacology, Immunology Therapeutic Area, Janssen Pharmaceuticals
Christopher Laing, MRCVS, PhD, Vice President, Science and Technology, University City Science Center
Dan Monaco, Partner, Drinker Biddle & Reath, LLP

MODERATOR
Todd Abrams, PhD, Senior Director, New Ventures and Business Development, Temple University

DESCRIPTION
LytPhage, a local start up company, out of Temple University are developing a novel antibiotic product that harnesses genetically-modified bacterial viruses (phage). In the “it takes a village” model, Temple University participated in several regional programs to move LytPhage and the technology forward. These programs were UCSC proof oc concept program QED, BioStrategy Partners Pharma Germinator, (matched using Temple's Technology Development Fund), and now the company has engaged in the newly developed UCSC program called Phase I Ventures.

On April 23rd a panel of speakers will cover how these programs helped to uncover the critical path for commercial development leading to new company formation (start up), large corporate collaboration, and (hopefully) to early financing.

ONLINE REGISTRATION
Early by April 17
LES Members: $40
Non-Members: $45

After April 17 and On-site
LES Members: $45
Non-Members: $50

Online Registration Deadline: April 20, 12 PM EDT

CANCELLATION POLICY
No refunds after April 20
Substitutions are permitted

SPEAKER BIOS
J. Todd Abrams

Dr. Abrams is presently the Senior Director, New Ventures and Business Development in Temple University’s Office of the Vice Provost for Research. His principal responsibilities are to help place new technologies on the critical path for commercial development and shape teams to establish new ventures to implement the commercial plan. Prior to joining Temple, Todd was Manager of JT ABRAMS CONSULTING where he supported institutions in our region to develop new approaches to support emerging technologies, as well as advise early stage technologies on how to access those new resources. Prior to consulting, Dr. Abrams Served as Director, Philanthropy and Business Development at the Lankenau Institute for Medical Research (LIMR) in Wynnewood PA, a position in which he expanded his interest in advancing early stage technologies. Among other responsibilities he oversaw LIMR’s technology development initiative, including its biotechnology incubator, technology transfer office, and philanthropy efforts. Before joining LIMR, Dr. Abrams was Executive Director, New Product Development at Meniscus Limited, a medical education and publishing company. He received a BA in biology from Lafayette College in Easton, PA, and a Ph.D. in immunology from the University of Pennsylvania. After receiving his Ph.D., Dr. Abrams spent over a decade performing cancer research, with positions at The Wistar Institute, The University of Miami School of Medicine, and Allegheny University of the Health Sciences now Drexel’s School of Medicine. Dr. Abrams also served as President, Foundation for Research Into Diseases of Aging (FRIDA) and Chaired the All Partners Committee of BioLaunch 611 + Keystone Innovation Zone. He previously served on the Board of Directors of BioStrategy Partners. Dr. Abrams is President of Intracell, LLC, which holds patents for the diagnosis and treatment of Alzheimer’s disease, and serves as a Board Member for the Philadelphia Israel Chamber of Commerce.

Daniel A. Monaco is a partner in the firm's Intellectual Property Practice Group. Formerly a shareholder with the Philadelphia intellectual property law firm of Seidel, Gonda, Lavorgna & Monaco, P.C., Dan joined Drinker Biddle & Reath when the two firms combined practices in 2001. He has been a registered patent attorney since 1981.

Intellectual Property. Dan has extensive experience in all aspects of intellectual property law. Concentrating on patent practice, Dan has prepared and prosecuted hundreds of U.S. patent applications, primarily in chemistry and biotechnology. He has represented diverse business and academic clients in matters pertaining to chemistry and chemical engineering. Representative chemical technologies include polymers, high performance coatings, chemical formulations, forestry products and industrial chemical processes; human and veterinary health care products, particularly pharmaceuticals such as anticancer, antithrombotic and antiviral drugs; methods and compositions for liquid lung ventilation in neonates; dental products; controlled delivery of pharmaceuticals, such as transdermal drug delivery; and diagnostic in vivo imaging of tumors and thrombi.

Dan has also represented clients in a broad spectrum of biotechnology applications from anticancer therapies and biopharmaceuticals to molecular genetics/biology and clinical diagnostics. Representative biological technologies include immunology; cancer vaccines, for example genetically engineered antitumor cellular immunogens; antisense oligonucleotide therapies; gene therapies, particularly targeted alteration of genes to correct genetic defects; nuclear transfer, cloning and the production of transgenic animals; generation of null mutant transgenic animals as disease models; monoclonal antibody technologies; genetic engineering of microorganisms; molecular geneticbased diagnostic methods; novel DNA and expressed proteins; peptide drugs, particularly antithrombotic and anticancer drugs; artificial blood substitutes; and agrobiotechnology.

Dan has represented major academic and business clients, individuals and startup companies in the Delaware Valley and elsewhere, before the United States Patent and Trademark Office and the federal courts. He has also prepared and negotiated numerous agreements involving the licensing of intellectual property rights. Working through an extensive network of overseas associates, Dan has counseled clients extensively in international patent protection, and has obtained extensive foreign patent protection for a wide variety of clients. He has also served as an expert witness during biotechnology litigation.

Publications. Dan is the coauthor of What the General Practitioner Should Know About Patent Law and Practice, American Law Institute – American Bar Association Committee on Continuing Professional Education.

In General. Dan is a member of the Philadelphia, Pennsylvania and American Bar Associations, the American Intellectual Property Law Association, and the American Chemical Society.

Daniel has been ranked by Chambers USA since 2004 in Intellectual Property Law, recognizing him as "a skilled attorney who is great at building client relationships." He was honored as Best Lawyers® Philadelphia Patent Lawyer of the Year for 2015.